@article{e1287c8e62d3403a97850e85fef484e2,
title = "HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models",
keywords = "squamous cell carcinoma, cetuximab, HER3, dimerization, xenograft",
author = "Dongsheng Weng and Guoqing Qian and Hongzheng Zhang and Magliocca, \{Kelly R.\} and Sreenivas Nannapaneni and Amin, \{Arm R.\} and Michael Rossi and Mihir Patel and Mark El-Deiry and Wadsworth, \{J. Trad\} and Zhengjia Chen and Khuri, \{Fadlo R.\} and Shin, \{Dong M.\} and Saba, \{Nabil F.\} and Chen, \{Zhuo G.\}",
note = "Wang D, Qian G, Zhang H, Magliocca KR, Nannapaneni S, Amin AR, Rossi M, Patel M, El-Deiry M, Wadsworth JT, Chen Z. HER3 targeting sensitizes HNSCC to cetuximab by reducing HER3 activity and HER2/HER3 dimerization: evidence from cell line and patient-derived xenograft models. Clinical Cancer Research. 2017;23(3):677-86.",
year = "2017",
month = feb,
day = "1",
language = "American English",
journal = "Pharmaceutical Science and Research",
}